Drug
TD-5108 clinical trials
Also written TD-5108 and Velusetrag.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2006 (1)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Cholinergic Antagonists source
Studies
Open first, then newest update. How each study uses TD-5108 is read from its arms, and is right about nine times in ten.
Testing it · 5
- Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).CompletedPhase 2Alfasigma S.p.A.NCT05724069Written as Velusetrag 15 mg once daily for 4 weeks.
- Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)CompletedPhase 2Alfasigma S.p.A.NCT00391820Written as TD-5108
- Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly SubjectsCompletedPhase 1Alfasigma S.p.A.NCT01467726Written as Velusetrag
- The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) StudyCompletedPhase 2Theravance BiopharmaNCT02267525Written as Velusetrag
- Phase 2 Study of Velusetrag in Diabetic or Idiopathic GastroparesisCompletedPhase 2Theravance BiopharmaNCT01718938Written as velusetrag dose 1
Codes
What other systems call TD-5108 · ClinicalTrials.gg INT005365
- MeSH (NLM) C533727TD-5108One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C533727 | TD-5108 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.